Mcm2-7 Replicative Helicase

The Mcm2-7 replicative helicase identified as a potential novel cancer-specific target to inhibit DNA replication initiation.

Aberrant DNA replication is a hallmark of cancer, however disease-specific inhibitors for this process are largely unavailable. Many chemotherapeutic agents target DNA replication but have deleterious side effects. As blocking DNA replication during elongation may itself cause genome instability, developing inhibitors to specifically block replication before it starts (during initiation) is an attractive approach. The Schwacha laboratory has identified the Mcm2-7 replicative helicase as a novel cancer-specific potential target in DNA replication initiation. 

Sanders J, Castiglione M, Shun T, Vollmer LL, Schurdak ME, Vogt A, Schwacha A. Validation of a high throughput screening assay to identify small molecules that target the eukaryotic replicative helicase. SLAS Discov. 2022. Epub 2022/01/22. PubMed PMID: 35058181 More

Click here include “Helicase” in the Additional Gift Instructions to support research at the UPDDI to develop novel therapeutic approaches to treating cancers.